FDA De Novo Listing Places UroLift System in the Urology Device Pathway
The FDA’s De Novo device database lists the UROLift System from Neotract, Inc. with De Novo number DEN130023, 510(k) number K130556, and a decision date of 12/13/2013. For clinicians and device specialists, that entry signals a formal regulatory classification for a novel medical technology rather than a therapeutic efficacy trial result, and it places the system within the agency’s pathway for lower-risk devices that do not fit an existing predicate category.
One line in a federal database can change the commercial and clinical life of a device.
What the Database Entry Establishes
The listing itself is spare, but the regulatory implications are not. FDA De Novo classification exists for devices that are sufficiently new that no appropriate predicate device is available, yet whose risk profile allows classification into a lower-risk category rather than automatic placement into Class III. In practical terms, the pathway gives a new device a legally recognized framework for marketing, postmarket oversight, and later reference by other manufacturers seeking clearance through an established route.
Here, the public record identifies UROLift System as the device name, Neotract, Inc. as the requester, and the agency’s decision date in December 2013. The record also ties the device to a 510(k) number, which helps situate the product within the broader regulatory filing ecosystem even when the De Novo review is the more important classification milestone. For a clinician reading the database, the entry confirms that the system crossed a federal threshold tied to device classification, not merely product development.
Why De Novo Classification Matters in Urologic Practice
Urologic implant technologies often sit at the intersection of anatomy, procedural technique, and device engineering. When a device reaches the market through De Novo classification, it usually reflects a judgment that the technology represents a new solution to an established clinical problem but does not belong in the highest-risk category reserved for devices with less certain safety or effectiveness profiles. That matters because office-based and minimally invasive urologic interventions rely on devices that must balance procedural simplicity with predictable safety in a patient population that may be older, medically complex, and sensitive to adverse urinary outcomes.
For the bedside clinician, the regulatory pathway is more than administrative housekeeping. It shapes how a device is understood by hospitals, payers, purchasing committees, and proceduralists who must decide whether a new tool fits their patient population and practice setting. A De Novo listing also matters for downstream evidence generation, because once a device is classified, subsequent studies and clearances often build around that framework rather than starting from a blank slate.
The Regulatory Milestone in Context
The FDA database page places the UROLift System among other devices cleared through the same classification process, including diagnostic and therapeutic technologies from different specialty areas. Within that list, the UROLift entry stands out because it reflects a device designed for a urologic procedural use case rather than a laboratory or imaging platform. The decision date of 12/13/2013 marks the point at which the agency completed its classification review and assigned the device a place in the regulatory system.
For clinicians, those details matter because they anchor a device’s commercial timeline and help explain when it became available for broader clinical adoption. Regulatory classification does not tell the full story of patient selection, symptom response, adverse events, or comparative performance. It does, however, establish the legal and scientific frame within which later clinical experience accumulates. In that sense, the database entry is a starting point for the device’s lifecycle, not its endpoint.
Why This Entry Still Resonates Clinically
Urologic procedural devices live or die on whether they can deliver a meaningful anatomic effect without creating new burdens in recovery, urinary function, or procedural logistics. A De Novo review reflects FDA recognition that the technology addresses a recognizable clinical need but does so through a mechanism or design that required its own classification rather than a simple comparison to older hardware. For clinicians, that often signals a device intended to occupy a niche where conventional surgery or pharmacologic management may not fully answer the problem.
The public record does not provide procedure details, patient selection criteria, or outcome data, and those limits should be kept in view. Even so, the classification itself is a clinically relevant event because it determines how the device enters practice, how future submissions reference it, and how quickly a novel urologic platform can move from regulatory novelty to routine consideration in specialty care.
A regulatory entry is not the same thing as evidence of benefit, but it is the gate through which the evidence must pass.